<html>
<head>PUBMED IDs for CTSL2</head>
<body bgcolor='#C5F0F2'><h1>CTSL2</h1><a href='https://pubmed.ncbi.nlm.nih.gov/16913838/'>Human cathepsin L rescues the neurodegeneration and lethality in cathepsin B/L double-deficient mice.</a> August 18  2006<br><a href='https://pubmed.ncbi.nlm.nih.gov/17869649/'>Polymorphisms in the cathepsin L2 (CTSL2) gene show association with type 1 diabetes and early-onset myasthenia gravis.</a> September 18  2007<br><a href='https://pubmed.ncbi.nlm.nih.gov/18500265/'>Immunohistochemical analysis of possible chemoresistance markers identified by micro-arrays on serous ovarian carcinomas.</a> May 27  2008<br><a href='https://pubmed.ncbi.nlm.nih.gov/18636205/'>Analysis of the methylation status of genes up-regulated by the demethylating agent, 5-aza-2'-deoxycytidine, in esophageal squamous cell carcinoma.</a> July 19  2008<br><a href='https://pubmed.ncbi.nlm.nih.gov/22452389/'>Expression of cysteine protease cathepsin L is increased in endometrial cancer and correlates with expression of growth regulatory genes.</a> July 24  2012<br><a href='https://pubmed.ncbi.nlm.nih.gov/23049944/'>Validation of the Cancer BioChip System as a 3D siRNA screening tool for breast cancer targets.</a> April 11  2012<br><a href='https://pubmed.ncbi.nlm.nih.gov/23542171/'>CTSL2 is a pro-apoptotic target of E2F1 and a modulator of histone deacetylase inhibitor and DNA damage-induced apoptosis.</a> April 30  2013<br></body></html>
